Healthcare Private Placement and M&A Transactions Review Week Ending February 5 2023

Alto Neuroscience: The company raised $60 million of Series B venture funding in a deal led by Lightswitch Learning and Alkeon Capital Management on January 30, 2023, putting the company’s pre-money valuation at $170 million. Novartis Pharma, Valor Equity Partners, Alpha Wave Global, and other investors participated in the round. The company is a developer of a psychiatric drug development platform intended to help patients with central nervous system (CNS) conditions.

Clearsense: The company raised $50 million of Series D venture funding in a deal led by HealthQuest Capital on January 31, 2023. UPMC Enterprises and Health Catalyst Capital Management also participated in the round. The company is a developer of a data platform-as-a-service technology designed to empower data confidence and speed future outcomes.

Ratio Therapeutics: The company raised $20 million of Series A venture funding in a deal led by Schusterman Family Investments and PointState Capital on February 2, 2023. The company is an operator of a pharmaceutical business developing next-generation precision radiopharmaceuticals for solid tumors.

Dimension Inx: The company raised $12 million of Series A venture funding in a deal led by Prime Movers Lab on February 1, 2023. KdT Ventures, Revolution/ROTR, Alumni Ventures, Solas BioVentures and Portal Innovation Ventures also participated in the round. The company is a developer of 3D-printed bioactive structures designed to offer organ and tissue regeneration and repair.

Genialis: The company raised $11.4 million of Series A1 venture funding from undisclosed investors on January 31, 2023, putting the company’s pre-money valuation at $23.6 million. The company is a developer of a data science and drug discovery platform intended to focus on new ways to treat disease.

Dxcover: The company raised GBP 7.5 million of Series A venture funding in a deal led by Eos Advisory on February 1, 2023. Mercia Asset Management, Norcliffe Capital, Scottish Enterprise, Mark Bamforth, SIS Ventures and University of Strathclyde Endowment also participated in the round. The company is a developer of a liquid biopsy platform designed for the early detection of cancer and other diseases.

Secretome Therapeutics: The company raised $6.9 million of venture funding from undisclosed investors on February 2, 2023. The company is a developer of cell-based therapy designed for people who experience a heart attack and patients with advanced heart failure.

SAMDI Tech / Charles River Laboratories International: The company was acquired by Charles River Laboratories International for $50 million on January 30, 2023. The company is a provider of label-free drug discovery solutions catering to biochemical targets and applications.

Chembio Diagnostic / Biosynex: The company reached a definitive agreement to be acquired by Biosynex  for $17.2 million on January 31, 2023. Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases.

Healion Bio / Tonix Pharmaceuticals Holding: The company was acquired by Tonix Pharmaceuticals Holding for an undisclosed amount on February 2, 2023. The company is a developer of medicines intended to cure and prevent infectious diseases for which there are few or no good treatment options.

Sense Biodetection / Sherlock Biosciences: The company was acquired by Sherlock Biosciences for an undisclosed amount on February 2, 2023. The company is a developer of user-centered diagnostic equipment designed to improve treatment and assist in decision-making in a decentralized healthcare system.